Assessment of the role of paraoxonase gene polymorphism (Q192R) and paraoxonase activity in the susceptibility to atherosclerosis among lead-exposed workers

Annals of Saudi Medicine

Volumn 31, Issue 5, 2011, Pages 481-487

  Kamal, Manal ^a   Fathy, Mona M ^a   Taher, Eman ^a   Hasan, Manal ^b   Tolba, May ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEAD; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BATTERY INDUSTRY; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; DNA POLYMORPHISM; EGYPT; ENZYME ACTIVITY; GENE; GENE ACTIVITY; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INDUSTRIAL WORKER; LEAD BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METAL INDUSTRY; MULTIPLE LINEAR REGRESSION ANALYSIS; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEAD; LINEAR MODELS; LIPIDS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; YOUNG ADULT;

EID: 80052906128     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.84625     Document Type: Article

References (38)

1. El-Gazzar RM, el-Hefny SA, Noweir KH, Shamy MY. Study of the lipoprotein pattern among workers exposed to lead. J Egypt Public Health Assoc 1989;64:571-85.
2. Antonowicz J, Andrzejak R, Lepetow T. Influence of heavy metals, especially lead, on lipid metabolism, serum alpha-tocopherol level, total antioxidant status, and erythrocyte redox status of copper smelter workers. J Anal Chem 1998;361:365-7. (Pubitemid 128790552)
3. Adonaylo VN, Oteiza PI. Pb2+ promotes lipid oxidation and alterations in membrane physical properties. Toxicol 1999;132:19-32. (Pubitemid 29042230)
4. Bhattacharjee CR, Dey S, Goswami P. Protective role of ascorbic acid against lead toxicity in blood of albino mice as revealed by metal uptake, lipid profiles and ultrastructural features of erythrocytes. Bull Environ Contam Toxicol 2003;70:1189-96. (Pubitemid 36621414)
5. Deng W, Poretz RD. Lead exposure affects levels of galactolipid metabolic enzymes in the developing rat brain. Toxicol Appl Pharmacol 2001;172:98-107. (Pubitemid 32373132)
6. Ito Y, Niiya Y, Kurita H, Shima S, Sarai S. Serum lipid peroxide dismutase activity in workers with occupational exposure to lead. Arch Occup Environ Health 1985;56:119-27. (Pubitemid 16240673)
7. Osterode W, Ulberth F. Increased concentration of arachidonic acid in erythrocyte membranes in chronically lead-exposed men. J Toxicol Environ Health Part A 2000;59:87-95. (Pubitemid 30072362)
8. Pataraia G. Some data of the lipid changes disturbing of blood, heart and lungs after lead exposition. Georgian Med News 2008;157:59-62.
9. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 2004;109: 3196-201
10. Gordon D. In: Durrington PN, editor. HDL: Where should the clinician stand? UK: Mark Allen Publishing 1992. p. 17-20.
11. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039-46
12. Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J 1993;294:829-34. (Pubitemid 23286573)
13. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24. (Pubitemid 19101597)
14. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 Is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276:44444-9.
15. La Du BN, Kulow W. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press Inc 1992. p. 51-91.
16. Sirivarasai J, Kaojarern S, Yoovathaworn K. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects. Chem Biol Interact 2007;168:184-92. (Pubitemid 46992662)
17. Yamane T, Matsumoto T, Nakae I, Takashima H, Tarutani Y, Tamaki S, et al. Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation. Hypertens Res 2006;29:417-22. (Pubitemid 44102809)
18. Leviev I, Richard W, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-21. (Pubitemid 30086111)
19. Cole TB, Li WF, Richter RJ, Furlong CE, Costa LG. Inhibition of paraoxonase (PON1) by heavy metals. Toxicol Sci 2002;66:312.
20. Debord J, Bollinger JC, Merle L, Dantoine T. Inhibition of human serum arylesterase by metal chlorides. J Inorg Biochem 2003;94:1-4. (Pubitemid 36293409)
21. Li WF, Pan MH, Chung MC, Ho CK, Chuang HY. Lead Exposure Is Associated with Decreased Serum Paraoxonase 1 (PON1) Activity and Genotypes. Environ. Health Perspect 2006;114:1233-6.
22. American heart association. What Your Cholesterol Levels Mean. Available from: http://www.american heart.org/presenter.jhtm?identifier=138.[Last accessed on 2009]
23. Henry RJ, Cannon DC, Winkelman JW. Clinical chemistry principles and technics. New York Harper and Row; 1974 p.1440.
24. Friedwold WT. Estimation of the concentration of LDL-C in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
25. Evenson ME. Spectrophotometric techniques. Tietz textbook of clinical chemistry. 3th ed. 1999. p. 75-93.
26. Sampson MJ, Braschi S, Willis G, Astley SB. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in type II diabetes. Clin Sci 2005;109:189-97. (Pubitemid 41117303)
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
28. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6. (Pubitemid 23063292)
29. OSHA (Occupational Safety and Health Administration): Occupational Safety and Health Standards, 200 Constitution Avenue, NW Washington, DC 20210: Toxic and Hazardous Substances: Lead 2003.
30. Chrysohoou C, Panagiotakos DB, Pitsavos C, Kosma K, Barbetseas J, Karagiorga M, et al. Distribution of serum lipids and lipoproteins in patients with beta thalassaemia major; an epidemiological study in young adults from Greece. Lipids Health Dis 2004;3:3.
31. Glew RH, Williams M, Conn CA, Cadena SM, Crossey M, Okolo SN. Cardiovascular disease risk factors and diet of fulani pastorialists of northern Nigeria. Am J Clin Nutr 2001;74:730-6. (Pubitemid 33101792)
32. Glew RH, Kassam HA, Bhanji RA, Okorodudu A, VanderJagt DJ. Serum lipid profiles and risk of cardiovascular disease in three different male populations in northern Nigeria. J Health Popul Nutr 2002;20:166-74.
33. Ademuyiwa O, Ugbaja RN, Idumebo F, Adebawo O. Plasma lipid profiles and risk of cardiovascular disease in occupational lead exposure in Abeokuta, Nigeria. Lipids Health Dis 2005;4:19.
34. Robert A. Hegele Paraoxonase Genes and Disease. Ann Med 1999;31:217-24.
35. Gonzalvo MC, Gil F, Hernandez AF, Villanueva E, Pla A. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 1997;105:169-79. (Pubitemid 27353307)
36. Bauters C, Amant C, Boullier A. Paraoxonase polymorphism (Gln192Arg) as a determinant of the response human coronary arteries to serotonin. Circulation 2000;101:740-74.
37. Rahmani M, Raiszadeh F, Allahverdian S, Kiaii S, Navab M, Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002;162:381-9. (Pubitemid 34457944)
38. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb Vasc Biol 2002;22:1329-33. (Pubitemid 34875745)